EP3215193A4 - Dosierungsschema für pegyliertes interferon - Google Patents

Dosierungsschema für pegyliertes interferon Download PDF

Info

Publication number
EP3215193A4
EP3215193A4 EP15857703.1A EP15857703A EP3215193A4 EP 3215193 A4 EP3215193 A4 EP 3215193A4 EP 15857703 A EP15857703 A EP 15857703A EP 3215193 A4 EP3215193 A4 EP 3215193A4
Authority
EP
European Patent Office
Prior art keywords
dosage regimen
pegylated interferon
pegylated
interferon
regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15857703.1A
Other languages
English (en)
French (fr)
Other versions
EP3215193B1 (de
EP3215193A1 (de
Inventor
Christoph Klade
Oleh ZAGRIJTSCHUK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharmaEssentia Corp
Original Assignee
PharmaEssentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PharmaEssentia Corp filed Critical PharmaEssentia Corp
Priority to EP23199969.9A priority Critical patent/EP4282485A3/de
Priority to SI201531980T priority patent/SI3215193T1/sl
Priority to HRP20231732TT priority patent/HRP20231732T1/hr
Priority to SM20240028T priority patent/SMT202400028T1/it
Priority to RS20231262A priority patent/RS65015B1/sr
Publication of EP3215193A1 publication Critical patent/EP3215193A1/de
Publication of EP3215193A4 publication Critical patent/EP3215193A4/de
Application granted granted Critical
Publication of EP3215193B1 publication Critical patent/EP3215193B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP15857703.1A 2014-11-06 2015-11-06 Dosierungsschema für pegyliertes interferon Active EP3215193B1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP23199969.9A EP4282485A3 (de) 2014-11-06 2015-11-06 Dosierungsplan für pegyliertes interferon
SI201531980T SI3215193T1 (sl) 2014-11-06 2015-11-06 Dozirna shema za pegiliran interferon
HRP20231732TT HRP20231732T1 (hr) 2014-11-06 2015-11-06 Režim doziranja pegiliranog interferona
SM20240028T SMT202400028T1 (it) 2014-11-06 2015-11-06 Regime di dosaggio per interferone pegilato
RS20231262A RS65015B1 (sr) 2014-11-06 2015-11-06 Režim doziranja pegiliranog interferona

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192114 2014-11-06
PCT/US2015/059410 WO2016073825A1 (en) 2014-11-06 2015-11-06 Dosage regimen for pegylated interferon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP23199969.9A Division EP4282485A3 (de) 2014-11-06 2015-11-06 Dosierungsplan für pegyliertes interferon

Publications (3)

Publication Number Publication Date
EP3215193A1 EP3215193A1 (de) 2017-09-13
EP3215193A4 true EP3215193A4 (de) 2018-07-25
EP3215193B1 EP3215193B1 (de) 2023-10-04

Family

ID=51945707

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15857703.1A Active EP3215193B1 (de) 2014-11-06 2015-11-06 Dosierungsschema für pegyliertes interferon
EP23199969.9A Pending EP4282485A3 (de) 2014-11-06 2015-11-06 Dosierungsplan für pegyliertes interferon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP23199969.9A Pending EP4282485A3 (de) 2014-11-06 2015-11-06 Dosierungsplan für pegyliertes interferon

Country Status (32)

Country Link
US (3) US11559567B2 (de)
EP (2) EP3215193B1 (de)
JP (2) JP6820841B2 (de)
KR (2) KR102724837B1 (de)
CN (1) CN107530403A (de)
AU (1) AU2015342908B2 (de)
BR (1) BR112017009193A2 (de)
CA (1) CA2964390A1 (de)
CL (1) CL2017001088A1 (de)
DK (1) DK3215193T3 (de)
EA (1) EA037151B1 (de)
ES (1) ES2966888T3 (de)
FI (1) FI3215193T3 (de)
HK (1) HK1243627A1 (de)
HR (1) HRP20231732T1 (de)
HU (1) HUE064909T2 (de)
IL (1) IL251627B (de)
LT (1) LT3215193T (de)
MX (1) MX389844B (de)
MY (1) MY191506A (de)
NZ (1) NZ730924A (de)
PH (1) PH12017500617B1 (de)
PL (1) PL3215193T3 (de)
PT (1) PT3215193T (de)
RS (1) RS65015B1 (de)
SG (1) SG11201702798PA (de)
SI (1) SI3215193T1 (de)
SM (1) SMT202400028T1 (de)
TW (1) TWI737583B (de)
UA (1) UA122867C2 (de)
WO (1) WO2016073825A1 (de)
ZA (1) ZA201702704B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134260A1 (en) * 2017-01-18 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
US20230131808A1 (en) * 2020-04-22 2023-04-27 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof
AU2022221496A1 (en) * 2021-08-29 2023-03-16 Pharmaessentia Corporation Method of Using Pegylated Interferon-alpha

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023826A1 (en) * 2007-08-16 2009-02-19 Pharmaessentia Corp. Protein-polymer conjugates
WO2010014874A2 (en) * 2008-07-31 2010-02-04 Pharmaessentia Corp. Peptide-polymer conjugates

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2001012214A2 (en) * 1999-08-13 2001-02-22 F. Hoffmann-La Roche Ag MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
AU6687000A (en) 1999-08-27 2001-03-26 Maxygen Aps New interferon beta-like molecules
CA2390292A1 (en) 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
WO2003044056A2 (en) 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
PT3025726T (pt) 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
US7345150B2 (en) 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
GEP20084487B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
EP2644206B1 (de) 2003-05-23 2019-04-03 Nektar Therapeutics PEG-Derivative die zwei PEG Ketten enthalten
EP1694347B1 (de) 2003-11-24 2013-11-20 BioGeneriX AG Glycopegyliertes Erythropoetin
KR20070042567A (ko) 2004-08-31 2007-04-23 파마시아 앤드 업존 캄파니 엘엘씨 글리세롤 분지쇄 폴리에틸렌 글리콜 인간 성장 호르몬공액체, 이의 제조 방법 및 이의 사용 방법
US7365127B2 (en) 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1869079A2 (de) 2005-03-11 2007-12-26 Siegfried Ltd. Die polymerproteinkonjugate und verfahren zu ihrer herstellung
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
EP1834963A1 (de) 2006-03-13 2007-09-19 Siegfried Ltd. Di-Polymer-Konjugate von Proteinen und Verfahren zur deren Erstellung
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
US20090035273A1 (en) * 2006-08-18 2009-02-05 Pepgen Corporation Combination treatment method with interferon-tau
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
KR101483814B1 (ko) 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
AU2007358605B8 (en) 2007-09-04 2012-02-02 Biosteed Gene Expression Tech. Co., Ltd. Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023826A1 (en) * 2007-08-16 2009-02-19 Pharmaessentia Corp. Protein-polymer conjugates
WO2010014874A2 (en) * 2008-07-31 2010-02-04 Pharmaessentia Corp. Peptide-polymer conjugates

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "History of Changes for Study: NCT02218047", 14 August 2014 (2014-08-14), XP055483741, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT02218047?V_1=View#StudyPageTop> [retrieved on 20180613] *
ANONYMOUS: "Pharmaessentia Corp.", 1 January 2012 (2012-01-01), XP055183344, Retrieved from the Internet <URL:http://www3.bio.org/bioasia-profiles/pdfs/196771.pdf> [retrieved on 20150415] *
ANONYMOUS: "Study Drugs - Proud-PV Phase III Study", 3 June 2014 (2014-06-03), XP055183229, Retrieved from the Internet <URL:http://web.archive.org/web/20140603131156/http://www.proud-pv.com/study-drugs.html> [retrieved on 20150415] *
EMA: "Orphan designation for pegylated proline-interferon alpha-2b", 20 December 2011 (2011-12-20), XP055483744, Retrieved from the Internet <URL:http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2011/12/WC500119793.pdf> [retrieved on 20180613] *
H. GISSLINGER ET AL: "Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera", BLOOD, vol. 126, no. 15, 10 August 2015 (2015-08-10), US, pages 1762 - 1769, XP055483671, ISSN: 0006-4971, DOI: 10.1182/blood-2015-04-637280 *

Also Published As

Publication number Publication date
US20250186552A1 (en) 2025-06-12
HUE064909T2 (hu) 2024-04-28
EA201790991A1 (ru) 2017-11-30
BR112017009193A2 (pt) 2018-01-30
EP3215193B1 (de) 2023-10-04
MY191506A (en) 2022-06-28
JP2021001184A (ja) 2021-01-07
ES2966888T3 (es) 2024-04-24
EP4282485A3 (de) 2024-01-17
HRP20231732T1 (hr) 2024-03-15
US12343381B2 (en) 2025-07-01
WO2016073825A1 (en) 2016-05-12
US20170326206A1 (en) 2017-11-16
US11559567B2 (en) 2023-01-24
CL2017001088A1 (es) 2018-01-12
EA037151B1 (ru) 2021-02-11
IL251627B (en) 2021-12-01
CA2964390A1 (en) 2016-05-12
DK3215193T3 (da) 2024-01-08
UA122867C2 (uk) 2021-01-13
LT3215193T (lt) 2024-01-25
SI3215193T1 (sl) 2024-02-29
KR20230079520A (ko) 2023-06-07
AU2015342908A1 (en) 2017-05-04
IL251627A0 (en) 2017-06-29
RS65015B1 (sr) 2024-01-31
TWI737583B (zh) 2021-09-01
AU2015342908B2 (en) 2021-06-24
EP3215193A1 (de) 2017-09-13
US20230131552A1 (en) 2023-04-27
PH12017500617A1 (en) 2017-09-04
PT3215193T (pt) 2023-12-15
KR20170083074A (ko) 2017-07-17
KR102540109B1 (ko) 2023-06-02
SG11201702798PA (en) 2017-05-30
HK1243627A1 (zh) 2018-07-20
NZ730924A (en) 2022-04-29
PH12017500617B1 (en) 2024-07-03
FI3215193T3 (fi) 2023-12-28
TW201618808A (zh) 2016-06-01
KR102724837B1 (ko) 2024-10-31
EP4282485A2 (de) 2023-11-29
JP2017533192A (ja) 2017-11-09
ZA201702704B (en) 2020-10-28
MX389844B (es) 2025-03-04
MX2017005244A (es) 2017-08-18
SMT202400028T1 (it) 2024-03-13
JP6820841B2 (ja) 2021-01-27
CN107530403A (zh) 2018-01-02
PL3215193T3 (pl) 2024-03-18

Similar Documents

Publication Publication Date Title
IL251822A0 (en) Variants of interferon alpha-2B
EP3134427A4 (de) Asx-spezifische proteinligase
IL247084B (en) dose fgh–18
IL254419A0 (en) New pharmaceutical uses
GB201521217D0 (en) Dosage regimens
EP3204092A4 (de) Indexierungsbereitstellungsvorrichtung
ZA201702704B (en) Dosage regimen for pegylated interferon
GB201418710D0 (en) Dosage regimen
EP3338805A4 (de) Wirkstoffkomplex
EP3185895A4 (de) Modifizierte vip3-polypeptide
GB201420311D0 (en) Pharmaceutical processing
ZA201800217B (en) Novel dosage regimen tiacumicin compound
IL266255A (en) New dosage regimen
EP3111944A4 (de) Antivirales medikament
HK40012526A (en) Novel dosage regimen
GB201617850D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen
HK1246704A1 (en) Medicament dosage determination
GB201418708D0 (en) Dosage regimen
HK1230480A1 (en) Solid antiviral dosage forms
AU2014904326A0 (en) Interferon alpha 2b variants
GB201400171D0 (en) Dosage regimen
GB201521015D0 (en) Novel pharmaceutical uses
GB201505526D0 (en) Novel pharmaceutical uses

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20231732T

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170414

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180626

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/60 20170101ALI20180620BHEP

Ipc: A61P 35/00 20060101ALI20180620BHEP

Ipc: A61K 38/21 20060101AFI20180620BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210507

111Z Information provided on other rights and legal means of execution

Free format text: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Effective date: 20210712

D11X Information provided on other rights and legal means of execution (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0047500000

Ipc: A61K0038210000

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015085987

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0047500000

Ipc: A61K0038210000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/02 20060101ALI20230418BHEP

Ipc: A61P 31/00 20060101ALI20230418BHEP

Ipc: A61P 19/08 20060101ALI20230418BHEP

Ipc: A61P 19/04 20060101ALI20230418BHEP

Ipc: A61P 19/00 20060101ALI20230418BHEP

Ipc: A61P 7/00 20060101ALI20230418BHEP

Ipc: A61P 35/00 20060101ALI20230418BHEP

Ipc: A61K 47/60 20170101ALI20230418BHEP

Ipc: A61K 38/21 20060101AFI20230418BHEP

INTG Intention to grant announced

Effective date: 20230515

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZAGRIJTSCHUK, OLEH

Inventor name: KLADE, CHRISTOPH

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LIN, KO-CHUNG

Inventor name: ZAGRIJTSCHUK, OLEH

Inventor name: KLADE, CHRISTOPH

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015085987

Country of ref document: DE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3215193

Country of ref document: PT

Date of ref document: 20231215

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20231211

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20240103

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231211

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20231004

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20230402521

Country of ref document: GR

Effective date: 20240209

Ref country code: SK

Ref legal event code: T3

Ref document number: E 43112

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20231732T

Country of ref document: HR

Payment date: 20231228

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20231732

Country of ref document: HR

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E023882

Country of ref document: EE

Effective date: 20231227

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1617036

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231004

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2966888

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240424

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E064909

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015085987

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20240705

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20231732

Country of ref document: HR

Payment date: 20241024

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250612

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: SM

Effective date: 20250801

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20231732

Country of ref document: HR

Payment date: 20251023

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251201

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20251024

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20251121

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20251119

Year of fee payment: 11

Ref country code: LU

Payment date: 20251119

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20251111

Year of fee payment: 11

Ref country code: DE

Payment date: 20251119

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20251027

Year of fee payment: 11

Ref country code: GB

Payment date: 20251120

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20251125

Year of fee payment: 11

Ref country code: MC

Payment date: 20251121

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20251022

Year of fee payment: 11

Ref country code: MK

Payment date: 20251022

Year of fee payment: 11

Ref country code: AT

Payment date: 20251120

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20251125

Year of fee payment: 11

Ref country code: FI

Payment date: 20251125

Year of fee payment: 11

Ref country code: DK

Payment date: 20251125

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HR

Payment date: 20251023

Year of fee payment: 11

Ref country code: FR

Payment date: 20251126

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20251120

Year of fee payment: 11

Ref country code: BE

Payment date: 20251119

Year of fee payment: 11

Ref country code: TR

Payment date: 20251028

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251201

Year of fee payment: 11

Ref country code: SE

Payment date: 20251119

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20251121

Year of fee payment: 11

Ref country code: CY

Payment date: 20251031

Year of fee payment: 11

Ref country code: CZ

Payment date: 20251029

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20251024

Year of fee payment: 11

Ref country code: LV

Payment date: 20251116

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20251024

Year of fee payment: 11

Ref country code: BG

Payment date: 20251120

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: EE

Payment date: 20251120

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20251030

Year of fee payment: 11

Ref country code: RO

Payment date: 20251023

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20251024

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20251023

Year of fee payment: 11

Ref country code: ES

Payment date: 20251229

Year of fee payment: 11